dihexa hgf/c-met potentiator Growth factors and their peptide mimetics for treatment of traumatic brain injury HGF and MET: From Brain

Novo Nordisk filed a New Drug Application for the CagriSema combination (cagrilintide 2.4 mg + semaglutide 2.4 mg) in December 2025, with an FDA decision anticipated in late 2026

The Cu-MBGN was synthesised using the sol-gel method and the resulting particles were highly regular, spherical nanoparticles with diameter ~ 100 nm, each with inherent porosity

Golvatinib also greatly reduced tumor burden in mouse xenograft models and blood vessel density in remaining tumors

This dual-mechanism approach shows promise for patients with treatment-resistant diabetes and obesity but requires careful medical supervision during dose escalation

And those different solutions create the cascading differences in dosing, efficacy, and side effects that matter to anyone choosing between them